| Literature DB >> 25090657 |
Xiao-Fang Wu1, Ai-Feng Wang2, Ling Chen2, En-Ping Huang2, Wei-Bing Xie2, Chao Liu3, Wei-Ye Huang2, Chuan-Xiang Chen2, Ping-Ming Qiu4, Hui-Jun Wang5.
Abstract
Methamphetamine (METH) belongs to Amphetamine-type stimulants, METH abusers are at high risk of neurodegenerative disorders, including Parkinson's disease (PD). However, there are still no effective treatments to METH-induced neurodegeneration because its mechanism remains unknown. In order to investigate METH's neurotoxic mechanism, we established an in vitro PD pathology model by exposing PC12 cells to METH. We found the expression of nitric oxide synthase (NOS), nitric oxide (NO) and α-synuclein (α-syn) was significantly increased after METH treatment for 24h, in addition, the aggregattion of α-syn and the S-nitrosylation of protein disulphideisomerase(PDI) were also obviously enhanced. When we exposed PC12 cells to the NOS inhibitor N-nitro-L-arginine(L-NNA) with METH together, the L-NNA obviously inhibited these changes induced by METH. While when we exposed PC12 cells to the precursor of NO L-Arginine together with METH, the L-Arginine resulted in the opposite effect compared to L-NNA. And when we knocked down the PDI gene, the L-NNA did not have this effect. Therefore, PDI plays a significant role in neurological disorders related to α-syn aggregation, and it suggests that PDI could be as a potential target to prevent METH-induced neurodegeneration.Entities:
Keywords: Methamphetamine; Neurodegeneration; Parkinson's disease; Protein disulphideisomerase; α-synuclein
Mesh:
Substances:
Year: 2014 PMID: 25090657 DOI: 10.1016/j.toxlet.2014.07.026
Source DB: PubMed Journal: Toxicol Lett ISSN: 0378-4274 Impact factor: 4.372